Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669232 | 0.96 | HTR2C (0.40) | HTR2CBTKMCHR1PRMT5MMP13 | |
| SCHEMBL23972481 | 0.85 | HTR2C (0.44) | HTR2CCYP3A4TNKSTNKS2PARP1 | |
| SCHEMBL23973269 | 0.84 | MCHR1 (0.42) | MCHR1CYP3A4 | |
| SCHEMBL23973342 | 0.83 | HTR2C (0.42) | HTR2CCYP3A4TNKSTNKS2PARP1 | |
| SCHEMBL23973129 | 0.81 | HTR2C (0.43) | HTR2CTNKSTNKS2PARP1 | |
| SCHEMBL23973229 | 0.80 | TNKS (0.40) | HTR2CCYP3A4TNKSTNKS2PARP1 | |
| SCHEMBL23972276 | 0.79 | TP53 (0.40) | HTR2CTNKSTNKS2PARP1 | |
| SCHEMBL23973233 | 0.79 | TNKS2 (0.39) | HTR2CMMP13TNKSTNKS2PARP1 | |
| SCHEMBL23973237 | 0.79 | HTR2C (0.40) | HTR2CMMP13TNKSTNKS2PARP1 | |
| SCHEMBL23973236 | 0.79 | TNKS2 (0.39) | HTR2CTNKSTNKS2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | HTR2C 123/4885BTK 2820/4885MCHR1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.